CAR-T 세포 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 종양 유형별, 적응증별, 치료 유형별, 표적 항원별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region and Competition, 2020-2030F
상품코드:1878814
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 CAR-T 세포 치료 시장은 2024년에 38억 7,000만 달러로 평가되었으며, 2030년까지 CAGR 22.77%로 성장하여 132억 5,000만 달러에 달할 것으로 예측됩니다.
키메라 항원 수용체(CAR) T 세포 치료는 환자의 T 세포를 유전자 조작하여 암세포에 특정 항원을 표적으로 하는 수용체를 발현하도록 하는 첨단 면역치료법입니다. 시장 확대는 주로 전 세계적으로 혈액암 발생률 증가, 재발 또는 난치성 환자군에서 높은 효과와 지속적인 반응 입증, 치료 적응증 확대 및 치료 접근성 향상을 위한 연구개발에 대한 막대한 투자에 의해 주도되고 있습니다.
The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030. Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.87 Billion
Market Size 2030
USD 13.25 Billion
CAGR 2025-2030
22.77%
Fastest Growing Segment
Acute Lymphoblastic Leukemia (ALL)
Largest Market
North America
Key Market Drivers
The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.
Key Market Challenges
The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.
Key Market Trends
Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy. However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.
Key Market Players
Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
AbbVie Inc.
Cellectis SA
Amgen Inc.
Pfizer Inc
Merck KgaA
Intellia Therapeutics, Inc.
Johnson & Johnson
Report Scope:
In this report, the Global CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
CAR-T Cell Therapy Market, By Product Type:
Yescarta
Kymriah
Tecartus
Breyanzi
Abecma
CAR-T Cell Therapy Market, By Tumor Type:
Hematological Malignancies
Solid Tumors
CAR-T Cell Therapy Market, By Indication:
Diffused Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Follicular Lymphoma (FL)
Mantle Cell Lymphoma (MCL)
Others
CAR-T Cell Therapy Market, By Targeted Antigen:
D 19
BCMA (B-Cell Maturation Antigen)
Others
CAR-T Cell Therapy Market, By End User:
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others
CAR-T Cell Therapy Market, By Treatment Type:
Single Treatment
Combination Treatment
CAR-T Cell Therapy Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global CAR-T Cell Therapy Market.
Available Customizations:
Global CAR-T Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global CAR-T Cell Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma)
5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
